RU-58841 vs Pyrilutamide (KX-826): Which Topical Antiandrogen?

The two most-used topical antiandrogens for pattern hair loss, compared on the things that actually matter: how they work, what the evidence says, and how they differ in practice.

The short answer

RU-58841 and pyrilutamide (research code KX-826) are the two topical antiandrogens the hair loss research community reaches for most. They do the same job in the same place, but they arrived from very different places: RU-58841 is a 1980s compound with a long, informal track record and no trials, while pyrilutamide is a modern drug candidate with real clinical data but a shorter history. If you want the longest-standing option and the harder hitter, that is RU-58841. If you want the one with human evidence behind it and a gentler reputation, that is pyrilutamide.

How they both work

Both are topical androgen receptor (AR) antagonists. They sit on the androgen receptor inside the hair follicle and compete with dihydrotestosterone (DHT) for that binding site. If DHT cannot dock, it cannot drive the follicle miniaturisation that produces pattern hair loss.

This is a different point of attack from finasteride and dutasteride. Those reduce how much DHT your body makes systemically. RU-58841 and pyrilutamide leave DHT levels alone and simply block its effect locally, at the scalp. In theory that means the action stays where you put it, which is the whole appeal of a topical antiandrogen. In practice, how well that holds up depends on the compound, the concentration, and the carrier it is dissolved in.

The evidence gap

This is the single biggest difference between them, and most comparisons skip over it.

RU-58841: no human trials

RU-58841 was developed by Roussel-Uclaf in the 1980s and studied for acne, hirsutism and hair loss. Development was discontinued and it never completed human clinical trials. What exists is decades-old animal work, including a controlled study in stump-tailed macaques that showed regrowth, plus a very large body of anecdotal reports from people who have used it for years. That community record is genuinely useful signal, but it is not the same as controlled human data, and RU-58841's safety profile in humans has never been formally established.

Pyrilutamide: actual clinical data

Pyrilutamide was designed from the start as a hair loss drug by Kintor Pharmaceutical. In March 2026 Kintor reported that KX-826 hit its Phase 3 primary endpoint in a 666-patient, 24-week, vehicle-controlled trial in China: about +15.3 hairs/cm2 from baseline at the 1.0% dose, roughly +10.65 hairs/cm2 over placebo (p<0.0001), with no drug-related serious adverse events reported. That is a real result. The caveats are equally real, though: it is company-reported top-line data, the trial was run entirely in China, and Kintor has faced repeated credibility questions from independent researchers. Promising signal, not a closed case.

Potency: pyrilutamide binds harder

On paper pyrilutamide is the more potent molecule. In binding assays its IC50 is around 0.28 nM, dramatically lower (stronger) than other topical AR antagonists like clascoterone. RU-58841 has less formal binding data published, but is generally considered less potent per molecule, which is part of why it is used at a much higher concentration (5% versus pyrilutamide's 0.5%).

Potency on a lab bench is not the same as results on a scalp, though. DHT itself binds the receptor very tightly, so a topical has to reach a high enough local concentration to actually outcompete it. That is why the carrier and concentration matter as much as the raw binding number, and why the community's real-world read is more nuanced than the assay data alone.

In practice: tolerability and reputation

The community consensus, across years of use, tends to land in the same place: RU-58841 is the harder-hitting, more irritation-prone option, and pyrilutamide is the cleaner, better-tolerated one. RU at 5% is more likely to cause scalp irritation, and because it is a stronger overall antiandrogen dose there is more discussion around systemic absorption at higher amounts. Pyrilutamide, used at a fraction of the concentration and with very low reported transdermal absorption, is more often described as side-effect-free by long-term users, though some report results plateauing around the six-month mark.

None of that is a substitute for controlled long-term safety data, which neither compound has in full. It is the honest read of what people report, not a promise of how any given sample will behave.

Side by side

So which one comes out ahead?

There is no universal answer, and any source offering one is selling something. The comparison comes down to which kind of evidence gets weighted more heavily:

• Longest track record and the harder-hitting reputation, at the cost of zero human trials: RU-58841.
• Actual human clinical data and a gentler profile, evidence over anecdote: pyrilutamide.

One honest note on the pairing: they share the same mechanism (androgen receptor blockade), so combining them is not obviously additive the way pairing two different pathways would be: a live debate in the research community, not a claim about synergy.

Shop RU-58841 5% Solution View product → Shop Pyrilutamide (KX-826) 0.5% Solution View product →

The honest caveats

Neither RU-58841 nor pyrilutamide is a licensed medicine, and Norwood Labs makes no medical or treatment claims about either. We sell them strictly as reference materials for laboratory research use. RU-58841 has never passed human trials and its human safety profile is not established. Pyrilutamide's clinical data is early, company-reported, and China-only. We do not give dosing advice. Every batch we sell ships with an independent Certificate of Analysis so you can verify what you actually received, which, given how often these compounds are underdosed or mislabelled, is the part that matters most.

Frequently asked

Is RU-58841 or pyrilutamide better?

There is no simple winner, and no head-to-head trial has ever been run. RU-58841 has the longest community track record and a reputation as the harder-hitting option, but it has never been through human clinical trials. Pyrilutamide is newer, more potent per molecule, and is the only one of the two with human trial data behind it. Which suits a given research context depends on whether track record or clinical evidence matters more.

Can RU-58841 and pyrilutamide be combined?

They share the same mechanism (both block the androgen receptor), so combining them is not clearly additive in the way that pairing two different mechanisms would be, a point the research community debates at length. Everything we sell is for laboratory research use only.

Does RU-58841 have clinical trials?

No. RU-58841 has never completed human clinical trials. The evidence base is decades-old animal studies (including a controlled stump-tailed macaque study) plus a large body of anecdotal community reports. Its safety and efficacy in humans have never been formally established.

How strong is the evidence for pyrilutamide?

Kintor Pharmaceutical reported that KX-826 (pyrilutamide) hit its Phase 3 primary endpoint in a 666-patient trial in China (about +10.65 hairs/cm2 over placebo at the 1.0% dose). That is real clinical data, but it is company-reported top-line data, conducted entirely in China, and Kintor has faced credibility questions in the research community. Treat it as a promising signal, not a settled result.

Are RU-58841 and pyrilutamide legal to buy in the UK?

Norwood Labs sells both strictly as reference materials for laboratory research use. Neither is a licensed medicine in the UK, and we make no medical or treatment claims.